HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

SRSF-1 and microvessel density immunohistochemical analysis by semi-automated tissue microarray in prostate cancer patients with diabetes (DIAMOND study).

AbstractOBJECTIVE:
To study the association between insulin receptors (isoforms α and β), insulin growth factor-1 (IGF1) and serine/arginine splicing factor 1 (SRSF-1) in patients with prostate cancer (PC) and diabetes.
MATERIALS AND METHODS:
We retrospectively analyzed data from 368 patients who underwent surgery for PC or benign prostatic hyperplasia (BPH) between 2010 and 2020 at the Department of Urology, University of Catania. Tissue microarray slides were constructed and they were stained for androgen receptor (AR), insulin receptor-α and -β, IGF1 (IGF1-R), Ki-67, and prostate specific membrane antigen (PSMA) expression using validated score.
RESULTS:
The final cohort was represented by 100 patients with BPH and 268 with PC, with a median age of 68 years. We found that SRSF-1 expression was associated with AR (odds ratio [OR]: 1.66), PSMA (OR: 2.13), Ki-67 (OR: 5.99), insulin receptor (IR)-α (OR: 2.38), IR-β (OR: 3.48), IGF1-R (OR: 1.53), and microvascular density (MVD) was associated with PSMA (OR: 3.44), Ki-67 (OR: 2.23), IR-α (OR: 2.91), IR-β (OR: 3.02), IGF1-R (OR: 2.95), and SRSF-1 (OR: 2.21). In the sub cohort of PC patients, we found that SRSF-1 expression was associated with AR (OR: 2.34), Ki-67 (OR: 6.77), IR-α (OR: 2.7), and MVD (OR: 1.98). At the Kaplan-Meier analysis, SRSF-1+ patients had worse 5- and 9-year biochemical recurrence (36% and 6%) respect to SRSF-1- (67% and 7%; p < .01) and similarly MVD+ patients (44% and 7%) respect to MVD- (64% and 8%; p < .01). Restricting the analysis only in patients with PC and diabetes, we found that SRSF-1+ was associated with Ki-67+ (OR: 8.75; p < .05) and MVD+ (OR: 7.5; p < .05).
CONCLUSIONS:
PC exhibits widespread heterogeneity in protein expression. In particular, the expressions of the SRSF-1 protein and of the MVD are associated with a worse prognosis and in particular with a greater cell proliferation. These results, although preliminary, may offer new future scientific insights with the aim of highlighting possible genetic alterations linked to a greater expression of SRSF-1 and associated with a worse prognosis.
AuthorsGiuseppe Broggi, Arturo Lo Giudice, Marina Di Mauro, Maria Giovanna Asmundo, Elisabetta Pricoco, Eliana Piombino, Rosario Caltabiano, Giuseppe Morgia, Giorgio Ivan Russo
JournalThe Prostate (Prostate) Vol. 81 Issue 12 Pg. 882-892 (09 2021) ISSN: 1097-0045 [Electronic] United States
PMID34196424 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2021 The Authors. The Prostate published by Wiley Periodicals LLC.
Chemical References
  • Biomarkers, Tumor
  • Blood Glucose
  • Ki-67 Antigen
  • SRSF1 protein, human
  • Serine-Arginine Splicing Factors
Topics
  • Aged
  • Biomarkers, Tumor (blood)
  • Blood Glucose (metabolism)
  • Cohort Studies
  • Diabetes Mellitus (blood, epidemiology, pathology)
  • Humans
  • Ki-67 Antigen (blood)
  • Male
  • Microvascular Density (physiology)
  • Microvessels (metabolism, pathology)
  • Middle Aged
  • Prostatic Neoplasms (blood, epidemiology, pathology)
  • Protein Array Analysis (methods)
  • Retrospective Studies
  • Serine-Arginine Splicing Factors (blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: